Literature DB >> 20651182

Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know.

Mizuki Nishino1, Jyothi P Jagannathan, Nikhil H Ramaiya, Annick D Van den Abbeele.   

Abstract

OBJECTIVE: The objectives of this article are to review the new Response Evaluation Criteria in Solid Tumors (RECIST) guideline, version 1.1, highlighting the major changes in the new version compared with the original RECIST guideline (version 1.0), and to present case examples with representative imaging.
CONCLUSION: Familiarity with the revised RECIST is essential in day-to-day oncologic imaging practice to provide up-to-date service to oncologists and their patients. Some of the changes in the revised RECIST affect how radiologists select, measure, and report target lesions.

Entities:  

Mesh:

Year:  2010        PMID: 20651182     DOI: 10.2214/AJR.09.4110

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  139 in total

1.  Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event.

Authors:  Mizuki Nishino; Lynette M Sholl; Mark M Awad; Hiroto Hatabu; Philippe Armand; F Stephen Hodi
Journal:  Cancer Immunol Res       Date:  2018-04-05       Impact factor: 11.151

Review 2.  Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.

Authors:  Mizuki Nishino; Sree H Tirumani; Nikhil H Ramaiya; F Stephen Hodi
Journal:  Eur J Radiol       Date:  2015-03-23       Impact factor: 3.528

3.  10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.

Authors:  Katherine M Krajewski; Yoko Franchetti; Mizuki Nishino; André P Fay; Nikhil Ramaiya; Annick D Van den Abbeele; Toni K Choueiri
Journal:  Oncologist       Date:  2014-04-22

4.  A Primer on RECIST 1.1 for Oncologic Imaging in Clinical Drug Trials.

Authors:  Kathleen Ruchalski; Marta Braschi-Amirfarzan; Michael Douek; Victor Sai; Antonio Gutierrez; Rohit Dewan; Jonathan Goldin
Journal:  Radiol Imaging Cancer       Date:  2021-05

5.  The radiographically diagnosed adrenal myelolipoma: what do we really know?

Authors:  Michael J Campbell; Mary Obasi; Bingling Wu; Michael T Corwin; Ghaneh Fananapazir
Journal:  Endocrine       Date:  2017-09-02       Impact factor: 3.633

6.  Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.

Authors:  Carole Durot; Sébastien Mulé; Philippe Soyer; Aude Marchal; Florent Grange; Christine Hoeffel
Journal:  Eur Radiol       Date:  2019-01-15       Impact factor: 5.315

Review 7.  Imaging guidelines and findings of extracranial glioblastoma.

Authors:  Daniel Thomas Ginat; Pamela W Schaefer
Journal:  J Neurooncol       Date:  2014-02-21       Impact factor: 4.130

8.  Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.

Authors:  Mizuki Nishino; Stephanie Cardarella; Suzanne E Dahlberg; David M Jackman; Nikhil H Ramaiya; Hiroto Hatabu; Michael S Rabin; Pasi A Jänne; Bruce E Johnson
Journal:  Lung Cancer       Date:  2012-12-14       Impact factor: 5.705

Review 9.  Imaging of Cancer Immunotherapy: Current Approaches and Future Directions.

Authors:  Mizuki Nishino; Hiroto Hatabu; F Stephen Hodi
Journal:  Radiology       Date:  2018-11-20       Impact factor: 11.105

Review 10.  Secondary and tertiary ovarian cancer recurrence: what is the best management?

Authors:  Simone Garzon; Antonio Simone Laganà; Jvan Casarin; Ricciarda Raffaelli; Antonella Cromi; Massimo Franchi; Fabio Barra; Ibrahim Alkatout; Simone Ferrero; Fabio Ghezzi
Journal:  Gland Surg       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.